Company Analysis
Sign in

Cumberland Pharmaceuticals Inc. (CPIX)

Nasdaq: CPIX · Pharmaceutical Preparations · Nashville,, TN · filing with the SEC since 2002
Full chart Alerts Compare
Grade6.0
◀ Past 5.5● Present 6.7▶ Future 5.4
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

33 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cumberland Pharmaceuticals Inc.’s names, not what it holds today.

Patents granted
33
33 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 2 in 2023
Applications published
80
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Cumberland Pharmaceuticals Inc. its own name
US, as the owner printed on each patent
33 granted
45 published
Cumberland Pharmaceuticals Inc. its own name
named as the applicant on its applications, in US
0 granted
35 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 10, 202412,161,632Compositions and methods of treating cardiac fibrosis with ifetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Nov 7, 202311,806,400Injectable ibuprofen formulationPharmaceuticalsCumberland Pharmaceuticals Inc.
Feb 7, 202311,571,412Thromboxane receptor antagonists in AERD/asthmaPharmaceuticalsCumberland Pharmaceuticals Inc.
Feb 23, 202110,925,860Compositions and methods of treating cardiac fibrosis with ifetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Aug 25, 202010,751,383Doses and methods for administering telavancinPharmaceuticalsCumberland Pharmaceuticals Inc.
Mar 10, 202010,583,126Compositions and methods of treating cardiac fibrosis with ifetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Oct 29, 201910,456,380Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonistsPharmaceuticalsCumberland Pharmaceuticals Inc.
Jun 11, 201910,314,824Compositions and methods of treating cardiac fibrosis with ifetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Sep 4, 201810,064,845Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonistsPharmaceuticalsCumberland Pharmaceuticals Inc.
Jul 10, 201810,016,399Compositions and methods of treating cardiac fibrosis with ifetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 24, 20252025/0235539INJECTABLE IBUPROFEN FORMULATIONPharmaceuticalsCumberland Pharmaceuticals Inc.
Apr 10, 20252025/0114334Ifetroban Treatment for Systemic SclerosisPharmaceuticalsCumberland Pharmaceuticals Inc.
Feb 13, 20252025/0049764Compositions and Methods of Treating Cardiac Fibrosis with IfetrobanPharmaceuticalsCumberland Pharmaceuticals Inc.
Jan 25, 20242024/0024481INJECTABLE IBUPROFEN FORMULATIONPharmaceuticalsCumberland Pharmaceuticals Inc.
Jan 25, 20242024/0024411METHODS FOR THE PREVENTION OR TREATMENT OF ANTHRAX INFECTIONPharmaceuticalsCumberland Pharmaceuticals Inc.
Nov 30, 20232023/0381147Ifetroban Treatment for Systemic SclerosisPharmaceuticalsCumberland Pharmaceuticals Inc.
Aug 31, 20232023/0270726Compositions and Methods of Treating Cardiac Fibrosis with IfetrobanPharmaceuticalsCumberland Pharmaceuticals Inc. · patent 12,161,632 granted from it
Jul 28, 20222022/0233473INJECTABLE SOLUTION OF NOREPINEPHRINEPharmaceuticalsCumberland Pharmaceuticals Inc.
Jul 14, 20222022/0218672Thromboxane Receptor Antagonists in AERD/AsthmaPharmaceuticalsCumberland Pharmaceuticals Inc.
Jul 7, 20222022/0211674Thromboxane Receptor Antagonists in AERD/AsthmaPharmaceuticalsCumberland Pharmaceuticals Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CPIX · research, not advice